TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HUTCHMED (China) ( (HK:0013) ) has provided an update.
HUTCHMED has appointed Professor Tan Shao Weng, Daniel as an Independent Non-executive Director and a member of its Technical Committee. Professor Tan brings over 20 years of oncology experience, particularly in thoracic, head, and neck malignancies, and drug development. His expertise in targeted therapies and clinical oncology is expected to bolster HUTCHMED’s strategic growth and innovation in cancer drug development. This appointment reflects HUTCHMED’s ongoing commitment to enhancing its leadership team with experienced professionals to drive forward its mission in the biopharmaceutical industry.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
Learn more about 0013 stock on TipRanks’ Stock Analysis page.